 Everolimus
"Everolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.
| Descriptor ID |
D000068338
|
| MeSH Number(s) |
D02.540.505.760.500
|
| Concept/Terms |
Everolimus- Everolimus
- SDZ RAD
- RAD, SDZ
- SDZ-RAD
- 40-O-(2-hydroxyethyl)-rapamycin
|
Below are MeSH descriptors whose meaning is more general than "Everolimus".
Below are MeSH descriptors whose meaning is more specific than "Everolimus".
This graph shows the total number of publications written about "Everolimus" by people in this website by year, and whether "Everolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 4 | 4 | | 2010 | 0 | 7 | 7 | | 2011 | 0 | 9 | 9 | | 2012 | 0 | 11 | 11 | | 2013 | 0 | 13 | 13 | | 2014 | 1 | 14 | 15 | | 2015 | 7 | 13 | 20 | | 2016 | 5 | 4 | 9 | | 2017 | 11 | 7 | 18 | | 2018 | 3 | 4 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Everolimus" by people in Profiles.
-
Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol. 2019 02; 46(1):57-64.
-
Slopis JM, Arevalo O, Bell CS, Hebert AA, Northrup H, Riascos RF, Samuels JA, Smith KC, Tate P, Koenig MK. Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial. Drugs R D. 2018 Dec; 18(4):295-302.
-
Wang H, Tian L, Liu J, Goldstein A, Bado I, Zhang W, Arenkiel BR, Li Z, Yang M, Du S, Zhao H, Rowley DR, Wong STC, Gugala Z, Zhang XH. The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. Cancer Cell. 2018 11 12; 34(5):823-839.e7.
-
Kazzaz F, O'Connell OJ, Vial MR, Stewart J, Grosu HB. Everolimus-induced Chylous Effusion. Am J Respir Crit Care Med. 2018 07 01; 198(1):120-122.
-
Zhang B, Fu D, Xu Q, Cong X, Wu C, Zhong X, Ma Y, Lv Z, Chen F, Han L, Qian M, Chin YE, Lam EW, Chiao P, Sun Y. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. Nat Commun. 2018 04 30; 9(1):1723.
-
Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018 05; 15(5):273-291.
-
Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol. 2018 03 10; 36(8):757-764.
-
Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan; 109(1):174-181.
-
Shatila W, Krajcer Z. Drug-coated balloons: "Do they still have a role in treating coronary artery disease?" Catheter Cardiovasc Interv. 2017 09 01; 90(3):387-388.
-
Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 10; 18(10):1411-1422.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|